<DOC>
	<DOCNO>NCT02780011</DOCNO>
	<brief_summary>This open label phase I trial design evaluate maximum tolerate dose , dose-limiting toxicity , pharmacokinetics , activity combination alsertib ( MLN8237 ) brentuximab vedotin patient relapsed/refractory CD30-positive lymphoma solid malignancy . Cohorts 3-6 patient receive escalate de-escalating dos MLN8237 base 3 + 3 design .</brief_summary>
	<brief_title>Alsertib ( MLN8237 ) Brentuximab Vedotin Relapsed/Refractory CD30-Positive Lymphomas Solid Malignancies</brief_title>
	<detailed_description>This investigator-initiated , open label phase I trial design evaluate maximum tolerate dose ( MTD ) , dose-limiting toxicity ( DLT ) , pharmacokinetics , activity brentuximab vedotin combination MLN8237 patient relapsed/refractory CD30-positive lymphoma solid malignancy . Brentuximab vedotin fix dose 1.8 mg/kg administer Day 1 every three week 30-minute outpatient intravenous infusion . MLN8237 orally administer two divided dos Days 1-7 . The start dose ( level 0 ) MLN8237 60 mg daily give two divided dos ( 30 mg qAM , 30 mg qPM ) .The dose MLN8237 escalate 20-mg increment 100 mg daily de-escalated 20-mg decrement 40 mg daily . The fixed dose brentuximab vedotin Day 1 daily dose MLN8237 Day 1-7 constitute one treatment cycle . If DLTs observe last study cohort , cohort expand include total 12 patient . If de-escalation dose require 2 patient experience DLTs , next low cohort study . If 2 patient experience DLTs , dose declare MTD . This cohort expand include 12 patient order study biological endpoint clinical benefit combination . If point expansion cohort phase trial 33 % patient treat MTD/maximum administer dose experience DLT , accrual additional patient level cease next low dose may explore .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care ; Relapsed refractory CD30positive lymphoma Hodgkin 's anaplastic large cell lymphoma CD30positive cancer testicular embryonal carcinoma , cutaneous angiosarcoma , nasopharyngeal nonkeratinizing carcinoma CD30positive solid tumor . CD30 positivity define ≥ 25 % CD30 expression immunohistochemistry . ( CD30 analysis perform inhouse CLIA CAPaccredited laboratory ) ; Male female patient age ≥ 18 year ; Adequate cardiac function ( cardiac ejection fraction ≥ 45 % ) ; Patients must receive least two prior therapy CD30positive lymphoma solid malignancy ; Absolute neutrophil count &gt; 1500/mm³ , platelet &gt; 100,000/mm³ , hemoglobin &gt; 8 g/dL . Values must obtain without need myeloid growth factor platelet transfusion support within 14 day first dose study treatment ; however , erythrocyte growth factor allow per American Society Clinical Oncology guideline ; Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) aspartate transaminase ( AST ) alanine transaminase ( ALT ) &lt; 2.5 x ULN . AST and/or ALT may 5 x ULN liver metastases present ; Adequate renal function define serum creatinine &lt; 2.0 mg/dL calculate creatinine clearance ≥ 30 mL/minute ; Eastern Cooperative Oncology Group performance status 0 2 ; Female patient must either : postmenopausal least one year screen visit , surgically sterilize , willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study ; Male patient , even surgically sterilize ( i.e. , postvasectomy status ) , must agree use acceptable contraceptive method course study 4 month last dose alisertib . Radiation therapy 25 % bone marrow . Whole pelvic radiation consider 25 % ; Prior allogeneic bone marrow organ transplantation ; Expected survival le 4 week ; Known gastrointestinal ( GI ) disease GI procedure could interfere oral absorption tolerance alisertib . Examples include limited partial gastrectomy , history small intestine surgery , celiac disease ; Known history uncontrolled sleep apnea syndrome condition could result excessive daytime sleepiness , severe chronic obstructive pulmonary disease ; Known cerebral meningeal disease ( Hodgkin 's lymphoma etiology ) , include sign symptom progressive multifocal leukoencephalopathy ; Symptomatic neurologic disease compromise normal activity daily live require medication ; Requirement constant intermittent administration proton pump inhibitor , H2 antagonist , pancreatic enzyme . Intermittent use antacid H2 antagonists allow ; Systemic infection require intravenous antibiotic therapy within 14 day precede first dose study treatment severe viral bacterial infection ; Absolute QT interval &gt; 460 msec presence &gt; 4.0 mEq/L potassium &gt; 1.8 mg/dL magnesium ; Myocardial infarction within 6 month prior enrollment New York Heart Association Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , electrocardiogram abnormality screen document investigator medically relevant ; Female patient pregnant breastfeeding . Confirmation subject pregnant must establish negative serum beta human chorionic gonadotropin pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilized woman ; Patient receive investigational drug within 14 day enrollment ; Serious medical psychiatric illness likely interfere participation clinical study ; Other severe acute chronic medical psychiatric condition , include uncontrolled diabetes , malabsorption , resection pancreas upper small bowel , requirement pancreatic enzyme , condition would modify small bowel absorption oral medication , laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make patient inappropriate enrollment study ; Diagnosed treat another malignancy within 3 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy ; Treatment clinically significant enzyme inducer , phenytoin , carbamazepine , phenobarbital , rifampin , rifabutin , rifapentine , St. John 's wort , within 14 day prior first dose alisertib ; Known history human immunodeficiency virus , hepatitis B , hepatitis C infection . Testing required absence clinical finding suspicion ; Prior administration Aurora A kinasetargeted agent , include alisertib ; Prior administration brentuximab vedotin allow patient experience disease progression treatment ; Known hypersensitivity recombinant protein , murine protein , excipient contain drug formulation brentuximab vedotin ; Concurrent recent ( within 2 week ) use strong cytochrome P450 ( CYP ) 3A4 inhibitor ketoconazole , itraconazole , clarithromycin , atanazir , inddinavir , nefazodone , neflinavir , ritonavir , saquinavir , telithromycin , voriconazole ; Concurrent recent ( within 2 week ) use potent CYP3A4 inducer dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. John 's wort ; Concurrent recent ( within 2 week ) use Pglycoprotein inhibitor cyclosporine , ketoconazole , ritonavir , saquinavir , tacrolimus , verapamil ; Receipt corticosteroid within 7 day prior first dose study treatment , unless patient take continuous dose 15 mg/day prednisone least 1 month prior first dose study treatment . Lowdose steroid use control nausea vomit allow . Topical steroid use permit . Inhaled steroid permit ; Inability swallow oral medication inability unwillingness comply administration requirement related alisertib ; Administration myeloid growth factor platelet transfusion within 14 day prior first dose study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>CD30+</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>ALCL</keyword>
</DOC>